繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-6

MB-6

Indication
Acting as Adjuvant for metastatic colorectal cancer
Product Advantages
reducing chemo-associated toxicity and enhancing efficacy of chemotherapy
Status
Phase III clinical trial is in progress
Competitive Edge
Oral capsule botanical drug, high safety, not much similar drugs currently on the market or under development
Potential Market
The analysis by GBI Research points out that the market value of colorectal cancer treatment will increase from 8.3 billion U.S. dollars in 2013 to 9.4 billion U.S. dollars in 2020
  • A series of preclinical studies had demonstrated that MB-6 reduced the incidence of colonic polyps and formation of tumor, prolonged survival rate as compared to chemotherapy alone when MB-6 was given together with 5-FU in colorectal cancer bearing mice.
  • MB-6 obtained USFDA and Taiwan Ministry of Health and Welfare (MOHW) phase II IND approval. In the Phase II clinical trials of patients with colorectal cancer in Taiwan, the combination of MB-6 and FOLFOX-4 standard treatment significantly prolonged progression-free survival (PFS) and overall survival, improved chemotherapeutic compliance, and improved FOLFOX-4-induced Neutropenia and reduce the dose of granulocyte colony stimulating factor (G-CSF) used

Phase II clinical trial


陕西快乐十分中奖技巧 大富豪棋牌微信版下载 晓游棋牌上海斗地主 快三平台 福彩 官网 69游戏盒子最新 河北快3app 心悦麻将代理加盟条件 山东福利彩票app 内蒙古十一选五开奖结果 上海哈灵麻将安卓版官方下载 516棋牌平台 广东十一选五开奖官网 乐禧白城麻将手机版 金牛棋牌作弊器下载 福建快3综合走势图 手机麻将作弊器通用 广东快乐10分走势图